Federal Register / Vol. 72, No. 192 / Thursday, October 4, 2007 / Notices 56775 

Application: Induction of wound 

healing through use of CpG 

oligodeoxynucleotides. 

Developmental Status: CpG 

oligonucleotides have been synthesized 

and preclinical studies have been 

performed. 

Inventors: Dennis Klinman and 

Takahashi Sato (NCI). 

Patent Status: U.S. Provisional 

Application filed 06 Sep 2007 (HHS 

Reference No. E–242–2007/0–US–01). 

Licensing Status: Available for 

exclusive or nonexclusive licensing. 

Licensing Contact: Peter A. Soukas, 

J.D.; 301/435–4646; 

soukasp@mail.nih.gov. 

Collaborative Research Opportunity: 

The Laboratory of Experimental 

Immunology of the National Cancer 

Institute is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize methods of increasing 

epithelial cell growth. Please contact 

John D. Hewes, Ph.D. at 301–435–3121 

or hewesj@mail.nih.gov for more 

information. 

Flexible, Polyvalent Antiviral Dendritic 

Conjugates for the Treatment of HIV/ 

AIDS 

Description of Technology: This 

technology describes the design and 

synthesis of flexible, polyvalent, 

antiviral conjugates of less than 200 kDa 

for the treatment of HIV/AIDS. These 

conjugates are mimetic of D1D2-Igatp, a 

high-molecular-weight (1 MDa) CD4- 

immunoglobulin fusion construct with 

extreme HIV neutralizing potency. Cryo 

electron microscopy suggests that the 

extreme potency of D1D2-Igatp is due to 

polyvalent presentation of a gp120- 

binding ligand on a flexible scaffold. 

The current prototype for the 

technology is a conjugate comprising 

soluble, two-domain human CD4 

covalently linked to a flexible 

poly(ethylene glycol)-PAMAM 

dendrimer scaffold. The construct is 

designed to retain a high degree of 

flexibility and polyvalence, and, at less 

than 200 kDa, is similar in size to 

successful antibody therapeutics 

currently on the market. Because it 

retains the key determinants of potency 

and the human CD4 moieties of D1D2- 

Igatp, this conjugate is expected to have 

the following unique set of HIV antiviral 

properties: (1) IC90 infectivity 

neutralization values in the nanomolar 

range against HIV primary isolates; (2) 

lack of susceptibility to viable escape 

mutations, because the ligand is CD4, 

and because CD4-independence evolves 

concomitantly with constitutive 

exposure of neutralization-sensitive, 

highly conserved coreceptor binding 

site epitopes; (3) indefinite control of 

HIV viral replication, without the need 

for combination therapy, arising from 

properties (1) and (2); (4) improved HIV 

viral replication control when used in 

combination with other Highly Active 

Antiretroviral Therapy (HAART); (5) 

improved prevention of seroconversion 

when used in combination with other 

HAART shortly following known 

exposure to HIV. 

Applications: Novel therapeutics for 

the treatment and prevention of HIV 

infection. 

Development Status: Synthesis and 

characterization in progress. 

Inventors: Sriram Subramaniam and 

Adam Bennett (NCI). 

Publication: AE Bennett et al. Cryo 

electron tomographic analysis of an HIV 

neutralizing protein and its complex 

with native viral gp 120. J Biol Chem., 

in press; published online ahead of 

print June 28, 2007. 

Patent Status: U.S. Provisional 

Application No. 60/932,464 filed 31 

May 2007 (HHS Reference No. E–213–

2007/0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Sally Hu, Ph.D.; 

301/435–5606; HuS@mail.nih.gov. 

Collaborative Research Opportunity: 

The Laboratory of Cell Biology of the 

National Cancer Institute is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize Flexible, Polyvalent 

Antiviral Dendritic Conjugates for the 

Treatment of HIV/AIDS. Please contact 

John D. Hewes, Ph.D. at 301–435–3121 

or hewesj@mail.nih.gov for more 

information. 

Monoclonal Antibodies to FusionActive Conformations of GP41 

Description of Technology: This 

technology describes three novel 

monoclonal antibodies, 2F12, 9C5 and 

11B8, which were derived against an 

HIV gp41 heptad-repeat entry inhibitor 

that mimics a structure of the HIV 

envelope protein fusion intermediate. 

These antibodies recognize the fusionintermediate and six-helix 

conformations of gp41 and are useful 

tools for high-throughput screening 

assays (HTS) to identify novel HIV–1 

inhibitors. Since the drugs identified in 

the assays using these monoclonal are 

expected to inhibit HIV infection in a 

different manner than current 

antiretroviral drugs, these antibodies 

may serve as valuable tools for 

screening for new drugs that may have 

activity against HIV strains that are 

resistant to currently available 

antiretroviral drugs. 

Applications: Research tool. 

Development Status: In vitro data 

available . 

Inventors: Carol D. Weiss and Russell 

A. Vassell (CBER/FDA). 

Related Publication: S Jiang et al. A 

screening assay for antiviral compounds 

targeted to the HIV–1 gp41 core 

structure using a conformation-specific 

monoclonal antibody. J Virol Methods. 

1999 Jun;80(1):85–96. 

Patent Status: HHS Reference No. E–

124–2007/0—Research Tool. Patent 

protection not being pursued for this 

technology. 

Licensing Status: Available for nonexclusive licensing as biological 

material. 

Licensing Contact: Sally Hu, Ph.D.; 

301/435–5606; HuS@mail.nih.gov. 

Dated: September 27, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–19649 Filed 10–3–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of Portfolio Analysis and 

Strategic Initiatives, Office of the 

Director, National Institutes of Health; 

Notice of Meeting 

Notice is hereby given of a planning 

meeting for the proposed Council of 

Councils, an external advisory panel to 

the NIH IC Directors and the Office of 

Portfolio Analysis and Strategic 

Initiatives (OPASI). 

The meeting will be open to the 

public, with attendance limited to space 

available. individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Council of Councils 

Planning Group. 

Date: November 8, 2007. 

Time: 8:30 a.m. to 5:00 p.m. 

Agenda: Among the topics proposed for 

discussion are: Role of the Council and 

timeline. 

Place: National Institutes of Health, 

Building 31, Conference Room 6, 9000 

Rockville Pike, Bethesda, MD 20892. 

Contact Person: Robert D. Hammond, PhD, 

Consultant To OPASI, 301–977–9307, 

bhammond@thehillgroup.com. 

Any interested person may file written 

comments with the committee by forwarding 


pwalker on PROD1PC71 with NOTICES
56776 Federal Register / Vol. 72, No. 192 / Thursday, October 4, 2007 / Notices 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number, and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s Web page: http:// 

opasi.nih.gov/council/ where an agenda and 

any additional information for the meeting 

will be posted when available. 

Dated: September 18, 2007. 

Alan M. Krensky, 

Director, Office of Portfolio Analysis and 

Strategic Initiatives (OPASI). 

[FR Doc. 07–4932 Filed 10–3–07; 8:45 am] 

BILLING CODE 4140–14–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Pediatric 

Nutrition. 

Date: October 22, 2007. 

Time: 3 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6116 

Executive Boulevard, Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Virginia P. Wray, PhD, 

Deputy Chief, Research Programs Review 

Branch, Research Programs Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, 6116 Executive Blvd., Room 

8125, Bethesda, MD 20892-8328, 301–496–

9236, wrayv@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 27, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–4925 Filed 10–3–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Heart, Lung, and 

Blood Initial Review Group; NHLBI 

Institutional Training Mechanism Review 

Committee. 

Date: November 15–16, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Admiral Fell Inn, 888 South 

Broadway, Baltimore, MD 21231. 

Contact Person: Charles Joyce, PhD, 

Scientific Review Administrator, Review 

Branch/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7196, Bethesda, MD 20892–7924, 301–435–

0288, cjoyce@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: September 28, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–4920 Filed 10–3–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

Board of Scientific Counselor, NHLBI. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Heart, Lung, and Blood 

Institute, including consideration of 

personnel qualifications and 

performance, and the competence of 

individual investigators, the disclosure 

of which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Board of Scientific 

Counselors, NHLBI. 

Date: October 29, 2007. 

Time: 9 a.m. to 4 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsic 

Avenue, Bethesda, MD 20814. 

Contact Person: Robert S Balaban, PhD, 

Scientific Director, Division of Intramural 

Research, National Institutes of Health, 

NHLBI, Building 10, CRC, 4th Floor, Room 

1581, 10 Center Drive, Bethesda, MD 20892 

301/496–2116. 

Information is also available on the 

Institute’s/Center’s home page: http:/// 

www.nhlbi.nih.gov/meetings/index.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: September 27, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–4930 Filed 10–3–07; 8:45 am] 

BILLING CODE 4140–01–M 


pwalker on PROD1PC71 with NOTICES